Table 2 Presentation of sensitivity and specificity and accuracy of serum biomarkers levels and fibrosis scoring systems to differentiate advanced from early stages of liver fibrosis in HCV patients

H.A

0.957^*

<0.001^*

0.910

1.00

>161

96.15

85.71

83.3

96.8

90.16

CO IV (μg/L)

0.901^*

<0.001^*

0.824

0.978

>181

76.92

94.29

90.9

84.6

86.89

COMP (μg/mL)

0.676^*

0.019^*

0.537

0.816

>27

57.69

74.29

62.5

70.3

67.21

APRI

0.762^*

0.001^*

0.637

0.886

>1.41

61.54

82.86

72.7

74.4

73.77

SHASTA

0.757^*

0.001^*

0.637

0.877

>1.22

100.0

51.43

60.5

100.0

72.13

NAFLD

0.901^*

<0.001^*

0.816

0.986

>1.55

84.62

94.29

91.7

89.2

90.16

FIB-4

0.927^*

<0.001^*

0.858

0.996

>1.85

96.15

82.86

80.6

96.7

88.52